Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Engineered exosome mimetics as targeted biological nanomedicines for pancreatic cancer

Award Number: R21CA283420
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/21/2024
PERIOD OF PERFORMANCE END DATE: 01/31/2027

Group Awards By:

View Award Description

Engineered exosome mimetics as targeted biological nanomedicines for pancreatic cancer - Project Summary/Abstract Pancreatic cancer (PC) is one of the most lethal forms of cancer in the United States (5-year survival rate below 10%). PC patients are usually diagnosed with a non-resectable disease (80-85%) and have a dismal prognosis with a survival period of only 3-6 months after the diagnosis. Nucleoside analogs (e.g., gemcitabine and fluorouracil) and platinum-based antineoplastics (e.g., oxaliplatin) are commonly used as chemotherapy for PC. When administered as free drugs, gemcitabine (Gem), fluorouracil (5-FU) and oxaliplatin (Oxa) display significant off-target toxicity causing life-threatening adverse effects in many patients. There is an urgent need to develop new therapeutic strategies consisting of delivery vehicles able to target PC cells, limit Gem, 5-FU and Oxa off-target toxicity and improve the overall anticancer response. We have recently patented a platform that uses an unbiased and quantitative screening algorithm for the discovery and validation of cancer-specific surface antigens. Our recently published results show that Intercellular Adhesion Molecule 1 (ICAM1), a transmembrane glycoprotein of the immunoglobulin superfamily, is aberrantly overexpressed in PC and can serve as a PC-specific target. Our results suggest that developing a novel ICAM1-based precision nanomedicine can be successfully utilized to treat PC patients. We have recently developed a magnetic extrusion technique to synthesize endosome-derived vesicles called exosome mimetics (EMs) in a highly efficient and reproducible manner. Our EMs share the same biological origin, morphology, nanosize and composition with exosomes, a class of natural cell-secreted extracellular vesicles. Our EM synthesis outperforms conventionally used exosome isolation and loading protocols in terms of particle yield, batch-to-batch consistency, reproducibility and loading efficiency. In this proposal,we leverage our expertise in cancer-specific antigen discovery and validation, bio- nanomaterial engineering, and exosome biology to test the novel hypothesis that EMs expressing ICAM1 nanobody and loaded with Gem, 5-FU and Oxa can be used as a novel delivery vehicle for PC therapy. We will synthesize EMs engineered with ICAM1 nanobodies that recognize and kill ICAM1-expressing PC cells and load them with Gem, 5-FU and Oxa. ICAM1-EM will exhibit increased tumor specificity and reduce Gem, 5FU and Oxa off-target delivery and toxicity. These innovative studies have the potential to lead to the development of novel EM-based therapies that can improve the efficacy of current cancer drug delivery. With key experimental tools, in vivo models and extensive experience in place, we will address the following Specific Aims: 1. To engineer ICAM1-targeted exosome mimetics (ICAM1-EMs) using magnetic extrusion method 2. To determine the efficacy of loaded ICAM1-Chemo-EMs in inhibiting PC growth and progression 3. To determine the pharmacokinetics (PK) and biodistribution of loaded ICAM1-Chemo-EMs


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	CHILDREN'S HOSPITAL CORPORATION, THE	300 LONGWOOD AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Detection and Diagnosis Research	000	2	12/2/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $206,869 )
2025	2025	CHILDREN'S HOSPITAL CORPORATION, THE	300 LONGWOOD AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Detection and Diagnosis Research	000	2	12/18/2024	NON-COMPETING CONTINUATION	$186,183
2025	2025	CHILDREN'S HOSPITAL CORPORATION, THE	300 LONGWOOD AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Detection and Diagnosis Research	001	2	5/30/2025	NON-COMPETING CONTINUATION	$20,686
														Subtotal = $206,869

Issue Date FY: 2024 ( Subtotal = $248,243 )
2024	2024	CHILDREN'S HOSPITAL CORPORATION, THE	300 LONGWOOD AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Detection and Diagnosis Research	000	1	2/21/2024	NEW	$248,243
														Subtotal = $248,243

Grand Total All Awards = $455,112

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Engineered exosome mimetics as targeted biological nanomedicines for pancreatic cancer

Award Number: R21CA283420

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/21/2024

PERIOD OF PERFORMANCE END DATE: 01/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer